Pioneering programmable therapeutics to reprogram the immune system and fight cancer with unprecedented precision, safety, and scalability.
Smarter, safer, and programmable medicine designed to overcome the limitations of current approaches.
Our platform enables readily available, cost-efficient therapeutics that remain competitive with existing biologics while eliminating the complex, patient-specific manufacturing challenges of cell therapies.
Our proprietary approach enables durable therapeutic effects through precise epigenetic mechanisms, achieving long-lasting gene modulation without DNA damage or risk of secondary malignancies.
This approach enables access to multiple targets—both traditionally druggable and previously undruggable—to reactivate the patient's natural anti-tumor immune response.
Our integrated platform combines multiple layers of targeting technology to ensure therapeutic payloads reach exactly the right cells, maximizing efficacy while minimizing off-target effects.
Advancing our platform from discovery through clinical development with a capital-efficient strategy.
Our platform uniquely combines the best attributes of existing modalities.
Interested in partnering, investing, or learning more about our platform? We'd love to hear from you.